
According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89 million. In Q3, Altimmune brought in $200.00 thousand in sales but lost $33.51 million in earnings.